Viewing nowHanubi Tablet 50mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201503213 · Approved 2015.05.27 · Insurance code 647805490
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is administered alone at the beginning of treatment, and if adequate blood sugar control is not achievable with monotherapy, it can be used in combination with metformin. Additionally, if blood sugar control is challenging with therapies such as sulfonylureas, thiazolidinediones, or insulin alone, this medication can be combined to enhance therapeutic effects. Even in cases of using multiple agents, this medication helps in managing blood sugar levels, contributing to diabetes management. Thus, this medication is used to improve blood sugar control in patients with type 2 diabetes.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (eGFR ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions in some patients. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking the medication, stop using it immediately and consult a doctor. While taking this medication, monitor carefully for symptoms of pancreatitis, which is inflammation of the pancreas, including severe abdominal pain, nausea, or vomiting. If such symptoms are suspected, discontinue use of this medication immediately and inform healthcare personnel. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered to individuals with a known allergy to this medication or its components. In patients with impaired kidney function, the excretion of this medication may slow down, thus dosage adjustments should be made based on renal function test results. In particular, it is recommended to administer lower doses to end-stage renal patients undergoing dialysis. This medication can be used alone or in combination with other diabetes treatments; however, when taken alongside insulin or sulfonylureas, the risk of hypoglycemia may increase, so closely monitor changes in blood sugar levels. Common side effects reported in clinical trials include upper respiratory infections, nasopharyngitis, headaches, diarrhea, and abdominal pain, most of which are mild or transient. If severe joint pain or skin blisters occurs while taking this medication, inform a doctor immediately and discontinue the use of the medication. Women who are pregnant or breastfeeding are advised against its use due to uncertain safety. Safety and efficacy have not been established in children and adolescents under 18 years of age. Elderly patients are at a higher risk for decreased kidney function; therefore, assessment of renal function before administration of this medication and dosage adjustments are necessary. In the event of overdose, symptomatic treatment is generally implemented. This medication can be partially removed through hemodialysis, so consider hemodialysis if needed. This medication has not shown significant interactions when taken with several other medications, but it is advisable to consult healthcare personnel if it is to be taken with certain drugs. If unexpected symptoms or side effects occur while taking this medication, immediately inform healthcare personnel and obtain appropriate medical care.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin disease, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthritis accompanied by severity and disability, vesiculobullous dermatosis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, elevated ALT, elevated AST, elevated serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container and kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage maintains the efficacy of the medication and ensures safe usage.
Light beige, double convex, round film-coated tablet
30 tablets/box [(10 tablets/PTP 3 pieces)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.